Who took part?
SURMOUNT-1 studied 2,539 adults with obesity, or overweight with at least one weight-related complication, without diabetes. They received weekly tirzepatide or placebo for 72 weeks, with lifestyle support and a dose-escalation period. SURMOUNT-1: once-weekly tirzepatide for obesity (NEJM, 2022) ↗
What were the average weight changes?
| Study group | Average body-weight change |
|---|---|
| Tirzepatide 5 mg weekly | −15.0% |
| Tirzepatide 10 mg weekly | −19.5% |
| Tirzepatide 15 mg weekly | −20.9% |
| Placebo | −3.1% |
The treatment-regimen analysis assessed results regardless of treatment discontinuation. Gastrointestinal effects were common and mostly mild or moderate. The study did not test Tyzepa-branded pens.
Why the time period matters
Seventy-two weeks is much longer than the first month of treatment. These values cannot be used to promise what will happen before a wedding, trip or short-term review. Ask your clinician to explain the purpose of early visits and how your own progress will be followed over time.
As a calculation example, a 15% change from 100 kg corresponds to 15 kg. It shows how a percentage works; it is not a forecast for a particular person. An average includes different responses and does not tell you exactly how an individual will tolerate treatment.
Higher study doses do not choose your dose
The research groups are not a self-treatment schedule. Selecting a prescribed strength involves your diagnosis, history, response and tolerability. Do not choose a pen based on the largest percentage in a table, and do not use a price combination as an escalation plan.
Bring these questions to follow-up: “Which research applies to my situation? What are we monitoring? What would make us reconsider the plan?” If you also have diabetes, ask about evidence and treatment goals relevant to that condition; this trial excluded diabetes.
Brand results and individual results are separate questions
The trial supports discussion of tirzepatide research. It does not establish the same outcomes for Tyzepa or interchangeability with another product. Review the Tyzepa and Mounjaro product guide for that distinction.
For practical planning, keep the safety guide and current price information next to your prescribed instructions. Evidence, tolerability and affordability all belong in the continuing conversation.
مریضوں کے لیے اردو خلاصہ
SURMOUNT-1 میں نتائج 72 ہفتوں کے بعد دیکھے گئے۔ اوسط وزن میں کمی ہر فرد کے لیے ضمانت نہیں۔ یہ تحقیق Tyzepa برانڈ کے پین پر نہیں ہوئی۔ زیادہ فیصد دیکھ کر طاقت منتخب نہ کریں؛ خوراک اور اگلا قدم معالج طے کرے۔
Sources
Source-based patient education prepared by the website editorial team. This article does not claim an independent clinician review. Bring individual medical questions to your prescriber.